NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY

INTRODUCTION: Severe Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in ~ 30% of Diffuse Large B Cell Lymphoma (DLBCL) patients treated with CAR-T cell therapy. The current treatment for severe ICANS is glucocorticoids, and this may be combined with tocilizumab for concurrent c...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Neuro Oncol
Κύριοι συγγραφείς: Mokhtari, Sepideh, Asquith, Justin, Bachmeier, Christina, Faramand, Rawan, Kim, Youngchul, Peguero, Edwin, Sahebjam, Solmaz, Jain, Michael, Vogelbaum, Michael, Davila, Marco, Forsyth, Peter, Locke, Frederick, Aleksandr, Lazaryan
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2020
Θέματα:
Neurological Complications of Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.538
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια